B A C K G R O U N D Description of the condition
Asthma is a chronic disease of the airways characterised by recurrent episodes of wheezing, breathlessness and cough, together with variable expiratory airflow limitation. Symptoms are frequently associated with airway inflammation and bronchial hyperresponsiveness (GINA 2016). Asthma can affect people of all ages, although childhood onset is common. Asthma is diagnosed clinically based upon evaluation of symptoms and response to pharmacotherapy. There is no specific diagnostic test, although spirometric measurement of reversible airflow limitation and indirect or direct tests of airway hyperresponsiveness can be useful (GINA 2016) . Currently, the number of people with asthma globally is estimated to be approximately 300 million; this number is predicted to be closer to 400 million by 2025 (WHO 2007) . Asthma is the most common chronic disease among children (Asher 2014). The Hospitalisations and emergency department visits attributable to asthma demonstrate an initial peak in school-aged children; however this is followed within days by increased hospitalisations in preschool children and a more blunted peak in adults up to the age of 50 years (Sears 2008). There is evidence that viral infections, particularly rhinovirus, may contribute to this seasonality (Johnston 1996; Johnston 2005; Thumerelle 2003); but also that sub-optimal asthma treatment may be a contributing factor (Johnston 2005). Not only do viral infections trigger asthma exacerbations but there is also evidence that asthmatic individuals are more susceptible to rhinovirus infection than those without asthma (Baraldo 2012; Wark 2005). Individuals at particular risk of asthma exacerbation have been identified as those with more severe disease, greater degree of atopy, and recent exacerbations (Teach 2015b).
Description of the intervention
A number of interventions including asthma education programmes, action plans, self-monitoring, and self-initiation of oral corticosteroid treatment have been shown to reduce both symptom exacerbations and need for unscheduled acute care in children with asthma (Bhogal 2006; Guevara 2003; Vuillermin 2011). Given that the seasonality of asthma exacerbations in school-aged children is predictable and repeatable, it is reasonable to assume that management strategies which anticipate increased risk in the autumn might reduce exacerbation frequency during this period. Whilst the exact aetiology of the seasonal peak in asthma exacerbations is not fully understood, any change in management aimed at improving asthma control in anticipation of the autumn school return, if successful, could offer protection against the increased risk recognised to be associated with this event. Therapies that have demonstrated to reduce the seasonal excess of exacerbations in the autumn, in addition to the annual number of exacerbations, include year-round treatment with the anti-IgE monoclonal antibody, omalizumab (Busse 2011); or with high-dose inhaled corticosteroids (Szefler 2008). Omalizumab is, however, an expensive treatment, whilst high-dose inhaled corticosteroids are associated with adverse effects upon growth and bone health (Sharek 2000; Wong 2000).
Given the pragmatic difficulties associated with minimising viral or allergen exposure, two main potential strategies remain which might reduce autumn asthma exacerbations whilst minimising treatment costs and adverse effects. The first strategy would be to add on, or increase, asthma pharmacotherapy before the autumn period; and the second strategy would be to focus upon treatment adherence and achieving symptom control before and during the autumn. It is anticipated that the greatest benefit from an intervention targeting seasonal exacerbations would be gained by school-aged children since the autumn peak in exacerbations is most pronounced in this age group. Similarly, greater benefit might be demonstrable in those at increased risk of exacerbation due to poor treatment adherence, disease severity, allergic phenotype or recent exacerbation. Add-on therapies include those aimed at reducing airway inflammation, such as corticosteroid preparations, macrolide antibiotics or leukotriene receptor antagonists. Alternatively, agents such as biologics which more specifically target the interaction between the immune response and viral infection might be selected (Durrani 2012; Gill 2010). Important considerations with respect to choice of intervention include onset of action and ease of administration, in addition to cost and adverse effect profile. Strategies to improve treatment adherence require adherence status to be assessed, and barriers leading to non-adherence to be identified and addressed. The success of adherence interventions can be increased by a number of strategies, including providing biofeedback (Feldman 2012), and increasing motivation via motivational interviewing techniques (Borrelli 2007). Nevertheless it is difficult to achieve sustained adherence (Jonasson 2000). Targeting adherence interventions to periods of increased exacerbation risk might increase their overall success.
How the intervention might work
Since the greatest peak in exacerbation rates is observed amongst school-aged children this potentially implicates some aspect of the school environment in the aetiology of the seasonal peak. Upon return to school in the autumn children are exposed to allergens and respiratory infections by close contact with their classmates (Cai 2011; Krop 2014). Moreover, it has been suggested that changes in routine during the summer holidays and lower perceived risk of cold weather or respiratory infection might be associated with both intentional reduction in preventer medication and potentially poorer adherence (Johnston 2005; Sears 2008). During the autumn months mould spores, which can act as a trigger for allergic asthma, are more abundant than at other times of the year (de Ana 2006). However, the sequential periods of peak risk demonstrated by school-aged children, younger children and adults suggest a transmissible agent is responsible. In support of this are findings from virological studies that demonstrate increased viral isolations during autumn, notably rhinovirus, from children with asthma compared to those without, with the highest rates of There is also evidence that baseline asthma control and treatment adherence might predict those most at risk. A higher rate of exacerbation has been reported in people prescribed bronchodilator therapy alone than in those prescribed an inhaled steroid or other preventer medication (Johnston 2005; Murray 2006). Furthermore, school-aged children with mild asthma but poor control, as evidenced by an exacerbation during the run-in period of 4 to 9 months, experienced a significant reduction in exacerbation frequency within a trial of seasonal omalizumab treatment (Teach 2015a). Exacerbation rate could not be significantly reduced in those with mild asthma but without a recent admission (Teach 2015a). Potentially any intervention based upon reinforcing or increasing adherence to regular treatment, monitoring symptoms to assess control or a seasonal enhancement of treatment might reduce ongoing airway inflammation and the likelihood of viral infection triggering an exacerbation.
Why it is important to do this review
Although the asthma epidemic observed in the 1980s and 1990s appears to have stabilised, a study from the Northern Hemisphere demonstrates that emergency care contacts due to asthma remain significantly higher in September than in other months (Larsen 2016). The recent trial of seasonal omalizumab administration demonstrated a significant reduction in exacerbation frequency amongst children with either severe asthma or poorly controlled mild to moderate disease (Teach 2015a). However, it is important to identify whether a similar effect can be achieved with less invasive and less expensive medications, particularly since in countries such as the UK, omalizumab can only be prescribed to people meeting strict severity criteria. It is estimated that up to 25% of annual hospitalisations for asthma occur in September (Johnston 2006). Moreover, acute exacerbations are the principal driver of the economic and social costs of asthma (Bahadori 2009; Hoskins 2000; Ismaila 2013). Therefore, interventions based upon an anticipatory change in asthma management, if successful, could substantially reduce both the overall exacerbation rate and the strain placed upon health services by multiple exacerbations during a relatively short period of time.
O B J E C T I V E S
To assess the effects of pharmacotherapy and behavioural interventions enacted in the lead-up to the school return during autumn which are designed to reduce asthma exacerbations in school-aged children during this period.
M E T H O D S Criteria for considering studies for this review

Types of studies
We will include randomised controlled trials (RCTs), quasi randomised controlled trials and observational studies. We will include studies reported as full-text, those published as abstract only, and unpublished data.
Types of participants
We will include studies which present data relating to school-aged children, 5 to 18 years old, with asthma. This is in recognition of the absence of a significant autumn peak in exacerbations in adults. We will also exclude studies of children below the age of 5 given the likely different aetiology and responses to treatment in preschool children; notably the high prevalence of wheezing in response to viral infection unresponsive to conventional inhaled or oral steroid asthma treatment.
Types of interventions
We will include studies comparing interventions aimed specifically at reducing autumn exacerbations with usual care where there is no systematic change in management in preparation for school return. Eligible interventions will include pharmacotherapy trials and behavioural or educational-based initiatives. Observational studies may have no usual care comparison group.
Types of outcome measures Primary outcomes
For controlled trials the primary outcome, depending upon what is reported, will be number of participants experiencing one or more asthma exacerbation during the autumn period (the first threemonth period following the autumn school return) or during the intervention period if this includes the autumn months. An exacerbation will be defined as increased asthma symptoms requiring treatment with oral steroids or hospitalisation. In observational studies, where there may be no usual care comparison group, we will assess the relative number of participants experiencing asthma exacerbations during the autumn months (standardised as the first three months following the autumn school return) compared to the remainder of the year.
Secondary outcomes
1. Number of participants experiencing exacerbations of asthma requiring hospitalisation.
2. Number of participants experiencing exacerbations of asthma requiring paediatric intensive care (PICU) admission.
3. Number of asthma-related deaths. 4. Asthma control, measured by standardised tool (e.g. Childhood Asthma Control Test (cACT) or Asthma Control Test (ACT)).
5. Asthma-related quality of life measured by standardised tool (e.g. Paediatric Asthma Quality of Life Questionnaire (PAQLQ) or Asthma Quality of Life Questionnaire (AQLQ)).
6. Days of schooling (or employment for those beyond school age) missed.
7. Adverse events (including serious adverse events). Secondary outcomes will only be considered in controlled trials. For each outcome data will be collected throughout the autumn period or the intervention period (as for the primary outcome) in both the intervention group and the standard therapy group. The number of young people requiring hospitalisation, PICU admission and number of asthma-related deaths as well as average questionnaire score, number of days education/employment missed or adverse events will be recorded. Reporting the primary outcome is not required as an inclusion criterion for the review.
Search methods for identification of studies Electronic searches
We will identify trials from the Cochrane Airways Group's Register of controlled clinical trials (CAGR), which is maintained by the Information Specialist for the Group. The Register contains trial reports identified through systematic searches of multiple bibliographic databases and handsearching of respiratory journals and meeting abstracts (please see Appendix 1 for further details). We will search all records in the CAGR using the search strategy in Appendix 2. We will also conduct a search of ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO trials portal (www.who.int/ictrp/en/). We will search all databases from their inception to the present, and we will impose no restriction on language of publication.
Searching other resources
We will check reference lists of all primary studies and review articles for additional references. We will search relevant manufacturers' websites for trial information.
We will search for errata or retractions from included studies published in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed) and report the date this was done within the review.
Data collection and analysis
Selection of studies
Two review authors (KP, KH) will independently screen titles and abstracts for inclusion of all the potential studies we identify as a result of the search and code them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We will retrieve the fulltext study reports/publication and two review authors (KP, KH) will independently screen the full-text and identify studies for inclusion, and identify and record reasons for exclusion of the ineligible studies. We will resolve any disagreement through discussion or, if required, we will consult a third review author (DK). We will identify and exclude duplicates and collate multiple reports of the same study so that each study rather than each report is the unit of interest in the review. We will record the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and outcome data which has been piloted on at least one study in the review. Three review authors (KP, KH, DK) will extract study characteristics from included studies in duplicate. We will extract the following study characteristics.
1. Methods: study design, total duration of study, details of any 'run-in' period, number of study centres and location, study setting, withdrawals, and date of study.
2. Participants: number, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and collected, and time points reported. 5. Notes: funding for trial, and notable conflicts of interest of trial authors. Two review authors (KP, DK) will independently extract outcome data from the included studies. We will note in the 'Characteristics of included studies' table if outcome data was not reported in a usable way. We will resolve disagreements by consensus or by involving a third review author (KH). One review author (KP) will transfer data into the Review Manager file (RevMan 2014). We will double-check that data is entered correctly by comparing the data presented in the systematic review with the study reports.
A second review author (DK) will spot-check study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (KP, KH) will independently assess the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We will resolve any disagreements by discussion or by involving another review author (DK). We will assess the risk of bias according to the following domains.
1. Random sequence generation. 2. Allocation concealment. 3. Blinding of participants and personnel. 4. Blinding of outcome assessment. 5. Incomplete outcome data. 6. Selective outcome reporting. 7. Other bias. We will grade each potential source of bias as high, low or unclear and provide a quote from the study report together with a justification for our judgment in the 'Risk of bias' table. We will summarise the risk of bias judgments across different studies for each of the domains listed. We will consider blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all-cause mortality may be very different than for a patient-reported pain scale). Where information on risk of bias relates to unpublished data or correspondence with a trialist, we will note this in the 'Risk of bias' table. When considering treatment effects, we will take into account the risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic review
We will conduct the review according to this published protocol and report any deviations form it in the 'Differences between protocol and review' section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios and continuous data as mean difference or standardised mean difference. We will enter data presented as a scale with a consistent direction of effect. We will undertake meta-analyses only where this is meaningful, such as when the treatments, participants and underlying clinical question are similar enough for pooling to make sense. We will narratively describe skewed data reported as medians and interquartile ranges. Where multiple trial arms are reported in a single trial, we will include only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) are combined in the same meta-analysis, we will halve the control group to avoid double-counting.
Unit of analysis issues
Asthma exacerbations will be considered a dichotomous outcome using participants as the unit of analysis. The odds of exacerbation in the intervention group during the intervention will be compared to the odds of exacerbation in individuals receiving standard therapy. For large-scale behavioural interventions (e.g. those that involve contacting young people in late summer to remind them of the need for treatment adherence), the unit of allocation may be primary care practice level rather than at the level of the individual. Where this is the case, results will only be included if the original trial accounted for clustering or if it is possible to adjust for this by calculating a design effect.
Dealing with missing data
We will contact investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study is identified as abstract only). Where this is not possible, and the missing data are thought to introduce serious bias, we will explore the impact of including such studies in the overall assessment of results by a sensitivity analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the trials in each analysis. If we identify substantial heterogeneity (I² > 50%) we will report it and explore possible causes by pre-specified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and examine a funnel plot to explore possible small-study and publication biases.
Data synthesis
We will use a Mantel-Haenszel random-effects model using Review Manager software (RevMan 2014) for all outcomes as we expect variation in effects due to differences in study populations and methods (Mantel 1959). We will perform a sensitivity analysis with a fixed-effect model when we encounter significant heterogeneity.
'Summary of findings' table
We will create a 'Summary of findings' table using the following outcomes: exacerbation occurrence (requiring oral steroids or hospitalisation); hospitalisation; PICU admission; asthma-related deaths; asthma control; asthma-related quality of life; days off school/employment missed; and adverse events. We will use the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta-analyses for the pre-specified outcomes. We will use methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) using GRADEpro GDT software. We will justify all decisions to down-or up-grade the quality of studies using footnotes and we will make comments to aid the reader's understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We recognise that intervention type or disease or severity might affect effect size and therefore plan to carry out the following subgroup analyses for all outcomes:
1. An analysis separating studies based upon pharmacological interventions from those based upon non-pharmacological interventions.
2. Analyses considering separately those with mild to moderate disease (intermittent bronchodilator only; or low/ moderate inhaled steroids with or without a single add-on therapy) and those with severe asthma (high-dose inhaled steroids; or two or more add on therapies). (High inhaled steroid dose beclomethasone equivalents daily: 5 to 12 years ≥ 800 mcg, older than 12 years ≥ 2000 mcg). We will use the identical primary and secondary outcomes in subgroup analyses as in the main analysis. We will use the formal test for subgroup interactions in Review Manager 5 to determine statistical significance of subgroup analyses (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses:
1. An analysis including only studies without missing data.
2. An analysis excluding cluster randomised trials (in case any benefit in cluster randomised trials arises due to the 'herd' effect of an intervention). We will also re-run analyses and compare results after sequential exclusion of each study from any meta-analysis. 
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